IMR Press / RCM / Volume 15 / Issue S1 / 10.3908/ricm15S1S005

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease
Show Less
1 HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Ireland
Rev. Cardiovasc. Med. 2014, 15(S1), 21–29;
Published: 20 January 2014
The nucleoside and nucleotide reverse transcriptase inhibitor (N[t]RTI) drug class remains an integral component of effective antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection. However, these drugs are associated with toxicities, through their off-target effects, that may significantly contribute to a number of long-term comorbidities, including coronary artery disease (CAD) and myocardial infarction (MI), recognized to occur with increased frequency in those with HIV undergoing treatment with ART. The contribution of N(t)RTI to CAD and MI may arise either indirectly through induction of metabolic toxicities such as dyslipidemia and insulin resistance, or directly through impact on pathologic pathways involved in development of MI, such as altered platelet responsiveness or endothelial dysfunction. This review focuses on the available data relating to use of individual N(t)RTI drugs and the drug class as a whole and CAD, with a focus on MI.
Antiretroviral therapy
Human immunodeficiency virus
Coronary heart disease
Nucleotide reverse transcriptase inhibitors
Cardiovascular disease
Back to top